Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shield Therapeutics ( (GB:STX) ) has issued an announcement.
Shield Therapeutics has updated the terms of its licensing agreement with Beijing Aosaikang Pharmaceutical for ACCRUFeR® in China, with ASK now expected to file for marketing authorisation with China’s NMPA in the first quarter of 2026, incorporating positive Phase 3 pediatric data that underpinned the US label extension to children aged 10 and over. Under the revised deal, Shield will receive a $7.9 million development milestone by 31 January 2026, new pricing-linked milestones of up to $3 million and royalties of up to 10% on Chinese sales, and it will use the milestone payment to fully settle and terminate its AOP Milestone Monetisation Agreement at a lower cost than previously anticipated, simplifying its capital structure and strengthening its financial position as it advances its commercial strategy in a key growth market.
The most recent analyst rating on (GB:STX) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency and iron deficiency anemia through its innovative oral iron therapy ACCRUFeR®/FeRACCRU® (ferric maltol). The drug, which has patent protection until the mid-2030s, is marketed in the US via an exclusive collaboration with Viatris and licensed to partners across Europe, Canada, China, Japan, and other Asia-Pacific territories, targeting a large and growing global market for iron deficiency treatments.
Average Trading Volume: 2,917,199
Technical Sentiment Signal: Buy
Current Market Cap: £109.9M
Learn more about STX stock on TipRanks’ Stock Analysis page.